BD treatment effectively suppresses the phosphorylation of proteins in the PI3K/AKT pathway, resulting in a significant reduction in COX-2 and PGES2 protein expression levels, which may lead to a notable decrease in PGE2 levels. The gene discussed is AKT1; the disease is Behcet disease.